File No.	Type of filing	Retention period
124–11		
124–20		
124–7, 124–7a	Subject files—Drafts, comments and correspondence concerning pro-	30 years.
	posed legislation submitted by the Senate and the House to the	
	Commission for comment.	
124–7b	Drafts of bills not yet reported in Congress that are submitted to the	30 years.
	Commission for comment.	
132–3	General Correspondence—Active companies. Inquiries and com-	10 years.
	plaints concerning companies registered under the various Acts ad-	
	ministered by the Commission.	
132–3	General Correspondence—Inactive companies (no longer required to	6 years.
	file reports with the Commission). Inquiries and complaints concern-	
	ing companies registered under the various Acts administered by	
	the Commission.	
132–3	General Correspondence—Miscellaneous. Requests for interpretation	6 years.
	of rules and regulations under the Acts administered by the Com-	
4.40	mission.	
140	Drafts, internal memoranda, correspondence concerning rules and	30 years.
000 007 1- 045 047	regulations under each of the Acts administered by the Commission.	00
206–, 207– to 215–, 917–	Reorganization proceedings under Chapters IX, X, XI of the Bank-	30 years.
265	ruptcy Act in which the Commission participates.	20
265–	Advisory Committees established by the Commission (correspond-	30 years.
Confidential treatment materials	ence, questionnaires, reports).	10 4000
Confidential treatment materials	Periodic reports and other materials containing contracts, commercial and financial information, disclosure of which would impair the value	10 years.
	thereof, submitted under confidential cover.	
CHR	SEC Chairman's Subject Case Files	20 years.
CHR	SEC Chairman's Chronological Files for Period 1972 to Present	Chairman's tenure in office plus 3
CHIC	SEC Chairman's Chloriological Files for Fellod 1972 to Flesent	vears.
CHR	SEC Chairman's General Subject File	Chairman's tenure in office plus 3
OTIIC	OLO Onamiario General Gubject File	vears.
COMM	SEC Commissioners' Files (excluding Chairman), 1934 to Present	Commissioner's tenure in office
	SEC Commissioners Theo (excitating chamman), 100 fto 1100cm	plus 1 year.
ENF	Investigative Case Files—Closed	Until closed plus 25 years.
ENF	Investigative Case Files—Inactive	Until inactive plus 25 years.
LIT	Litigation files:	
	1. Briefs	25 years.
	2. File contents other than briefs	10 years.
S7	Issuance, amendment or rescission of rules under the various Acts—	30 years (permanent).
	public comments and views, transcript of hearings, correspondence.	, ,
XX	Reports of internal inquiries:	
	Supporting documentation	Until date of final action plus 5
		years, if no report is issued, or
		until date of final report plus 5
		years.
	2. Final reports	5 years.

By the Commission.
Dated: September 22, 1995.
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 95–24032 Filed 9–27–95; 8:45 am]
BILLING CODE 8010–10–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## 21 CFR Part 520

## Oral Dosage Form New Animal Drugs; Milbemycin Oxime

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Ciba-Geigy Animal Health, Ciba-Geigy Corp. The supplemental NADA provides for the use of milbemycin oxime tablets in puppies 4 weeks of age or greater and 2 pounds (lb) of body weight or greater for the prevention of heartworm disease, control of adult hookworm infections. and removal and control of adult roundworm and whipworm infections. **EFFECTIVE DATE:** September 28, 1995. FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for Veterinary Medicine (HFV-112), Food and Drug

FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for Veterinary Medicine (HFV–112), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–0614.

SUPPLEMENTARY INFORMATION: Ciba-Geigy Animal Health, Ciba-Geigy Corp.,

P.O. Box 18300, Greensboro, NC 27419–8300, filed a supplement to NADA 140–915 for INTERCEPTOR® (milbemycin oxime) tablets. The NADA provides for veterinary prescription use of 2.3-, 5.75-, 11.5-, and 23.0-milligrams INTERCEPTOR® tablets for use as an

INTERCEPTOR® tablets for use as an anthelmintic in dogs in the prevention of heartworm disease caused by *Dirofilaria immitis*, control of adult *Ancylostoma caninum* (hookworm), removal and control of adult *Toxocara canis* (roundworm), and *Trichuris vulpis* (whipworm) infections in dogs. The supplement provides for use of the product to treat puppies 4 weeks of age or greater and 2 lb of body weight or greater for the same infections.

The supplemental NADA 140–915 is approved as of August 16, 1995, and the regulations are amended by revising 21 CFR 520.1445(c)(2) and (c)(3) to reflect